| INTRODUCTION
Coccidioidomycosis is an infection due to the dimorphic, soil-dwelling fungus Coccidioides. In the USA, the disease is endemic to the San Joaquin Valley of California and to the desert southwest, particularly the central portion of Arizona. Infection is most commonly acquired by inhalation of coccidioidal arthroconidia, and pneumonia is the most common presentation. 1 However, severe disease, including extrathoracic dissemination, may occur among individuals with suppressed cellular immunity. 2 The incidence of symptomatic coccidioidomycosis has been found to be increased among patients who receive allogeneic solid organ transplants, including heart, 3 kidney, 4 and liver. 5 However, despite a recent review, 6 no series have been reported in those who have undergone lung transplantation (LT). This report describes an analysis of cases of coccidioidomycosis among heart-lung, as well as single-and bilateral-lung transplant recipients at a single transplantation center located in the coccidioidal endemic region over a period of 24 years.
| MATERIALS AND METHODS
We performed a retrospective chart review on all LT cases performed at the University of Arizona Medical Center from November 1985 
| RESULTS
Transplantations were performed in 189 patients for the time period studied. Thirteen individuals required a second transplantation.
Procedures included 51 heart-lung transplants, performed between Table 1 details the characteristics of the patients. More than two-thirds of the patients resided in the coccidioidal endemic region at the time of transplantation.
Screening for evidence of coccidioidomycosis prior to transplantation varied. In general, patients were asked if they had a previous diagnosis of coccidioidomycosis and a plain chest radiograph was obtained. In some cases prior to 2000, spherule-based skin testing was performed. If patients had evidence of coccidioidomycosis based on any of the above studies, coccidioidal serological tests were obtained, but were otherwise not done on a routine basis. had evidence of old granulomatous disease on plain chest radiograph (Table 1 ). In 11 of these cases, patients received antifungal therapy during the post-transplantation period.
Among the 189 subjects, coccidioidomycosis occurred after transplantation in 11 instances ( Overall, the median time from transplantation to development of coccidioidomycosis was 3 months with a range of 1-56 months (Table 2) . No subject developed coccidioidomycosis after a second transplantation. In 9 instances, coccidioidomycosis was diagnosed within 1 year after transplantation. In one instance (Case 11, Table 2 ), a 42-year-old woman who received a single-lung transplant for interstitial pulmonary fibrosis developed active pulmonary coccidioidomycosis >4 years after transplantation. She had no history of coccidioidomycosis prior to transplantation.
In another instance (Case 1, Table 2 ), active coccidioidomycosis developed during chronic rejection >5 years after transplantation.
This case requires further amplification. In January 2003, 22 months prior to LT, the patient was seen at an outside facility. A chest radiograph demonstrated multiple alveolar and interstitial pulmonary infiltrates and a coccidioidal serology was reported as positive. The patient was placed on fluconazole, but this was discontinued after 2 months.
Because of progressive dyspnea, he was evaluated at the University T A B L E 2 Characteristics and outcomes of the 11 lung transplant recipients who developed coccidioidomycosis in the post-transplantation period Case no. Two deaths were associated with coccidioidomycosis. One death was directly attributable with the finding of diffuse pulmonary coccidioidomycosis on autopsy. In the other, coccidioidomycosis was a contributing cause of death based on autopsy. The direct cause of death was necrotizing pneumonia from Pseudomonas aeruginosa, but coccidioidal spherules were also identified in the lungs. Both patients died within 2 months after LT.
As shown in Table 3 
| DISCUSSION
We present the first reported case series, to our knowledge, of coccidioidomycosis occurring after LT within the coccidioidal endemic We identified two cases of possible donor-derived coccidioidomycosis. In one instance, it was based on the finding of an isolated positive coccidioidal IgM EIA serology, which may have been falsely positive. 9 One patient died rapidly without a diagnosis and the other, who received antifungal therapy, survived and died of other causes.
Given this experience and that of other transplantation centers, Patients on antifungal therapy for any reason had a significantly decreased risk for developing post-transplantation coccidioidomycosis. This observation is in accordance with a recent study on orthotopic liver transplantation performed in the coccidioidal endemic region.
That report 17 found that universal antifungal prophylaxis with 200 mg of daily fluconazole for the first year after transplantation resulted in no cases of post-transplantation coccidioidomycosis compared to an incidence of 2.6% among those receiving targeted prophylaxis based on a pre-transplant history of coccidioidomycosis or asymptomatic coccidioidal seropositivity. Our study gives support to the concept that antifungal prophylaxis, at least for the first year after transplantation, could reduce the incidence of post-transplantation coccidioidomycosis within the endemic area.
The immunosuppression regimen changed dramatically over the course of the study. While it is possible that this had an effect on the number of cases of post-transplantation coccidioidomycosis,
this cannot be definitively concluded by our results. It is interesting that no cases of post-transplantation coccidioidomycosis occurred in heart-lung recipients and none received antifungal prophylaxis. The reasons for this difference are unclear. One explanation is that these transplants were performed between 1985 and 1989, a time when the incidence of coccidioidomycosis in Arizona was far lower than it was in later decades.
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Weaknesses of this study include its retrospective nature, the fact 
